Safety and Efficacy of the CGuard™ Carotid Stent System in Carotid Artery Stenting (C-GUARDIANS)
Objective: 30-day assessment of the safety and efficacy of the CGuard™ carotid stent system in patients (N=316) at high risk for carotid endarterectomy with carotid artery stenosis (25% symptomatic).
Conclusion: Treatment with the CGuard™ carotid stent system with embolic protection had a low incidence of stroke, death, or MI post-procedure to 30-day follow-up.
A Prospective, Multicenter Study of a Novel Mesh-Covered Carotid Stent: The CGuard™ CARENET Trial (Carotid Embolic Protection Using MicroNetTM)
Objective: Evaluate the feasibility of the CGuard™ Carotid Embolic Protective Stent system in treating carotid artery lesions in consecutive patients (N=30) suitable for carotid artery stenting.
Conclusion: The CGuard™ system is feasible for patients undergoing carotid artery stenting. In addition, the benefit of using CGuard™ may extend throughout the stent healing period.
Novel PARADIGM in carotid revascularisation: Prospective evaluation of All-comer peRcutaneous cArotiD revascularisation in symptomatic and Increased-risk asymptomatic carotid artery stenosis using CGuard™ MicroNetTM-covered embolic prevention stent system
Objective: To determine (1) periprocedural and 30-day clinical safety and efficacy of the MicroNetTM-covered embolic prevention carotid stent system (MN-EPS) in routine use for unselected carotid stenosis (CS) patients undergoing CAS (N=101), as well as (2) feasibility of MN-EPS post-dilatation optimization to minimize residual stenosis after CAS.
Conclusion: These increased-risk consecutive patient data (1) indicate the safety and efficacy of routine MN-EPS use in achieving endovascular reconstruction across all-comer CS lesion subsets and (2) are consistent with MN-EPS protection against cerebral events extending throughout the stent healing period.
